Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication
Open Access
- 24 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 41 (9), 1255-1257
- https://doi.org/10.1038/s41401-020-0430-6
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human SubjectsClinical Pharmacokinetics, 2013
- ACE2, a promising therapeutic target for pulmonary hypertensionCurrent Opinion in Pharmacology, 2011
- Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive AgentsHypertension, 2008
- Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lungJournal of Cellular Biochemistry, 2007
- ACE PolymorphismsCirculation Research, 2006
- Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitorVirology, 2006
- Ace revisited: A new target for structure-based drug designNature Reviews Drug Discovery, 2003
- Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarctionJournal of the Renin-Angiotensin-Aldosterone System, 2000
- Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trialsJournal of Hypertension, 1996